Apply now through December 13 for HF-Cert™! Open to members of the HF team in many disciplines!
2019 | HFSA

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM

Practice News Industry

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM

For more information, visit the MyoKardia website.